Insys Therapeutics (NASDAQ: INSY) reported Q2 EPS of ($0.11), in-line with the analyst estimate of ($0.11). Revenue for the quarter came in at $42.6 million versus the consensus estimate of $36.81 million.

Highlights of and subsequent to the second quarter of 2017 include:

• Total net revenue was $42.6 million, compared to $69.2 million for the second quarter of 2016;
• Net loss totaled $8.2 million, or ($0.11) per basic and diluted share, compared to net income of $6.0 million, or $0.08 per basic and diluted share, for the second quarter of 2016;
• Appointed Andrew G. Long, a seasoned finance executive with three decades of experience in the life sciences, bio-pharma and industrial sectors, as Chief Financial Officer;
• Further strengthened management team adding four key pharmaceutical industry veterans in leadership positions; and
• SYNDROS™ (dronabinol oral solution) (CII), the first and only FDA-approved liquid dronabinol, is now available for health care professionals to prescribe and stocked with most major wholesalers for retail pharmacy ordering or through the INSYS Specialty Pharmacy Network.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.